CIGOGNE FUND

M&A Arbitrage 30/11/2025



Assets Under Management :

196 908 968.67 €

Net Asset Value (O Unit): 54 778.05 €

PERFORM	PERFORMANCES												
	January	February	March	April	May	June	July	August	September	October	November	December	YTD
2025	0.31%	0.24%	0.20%	0.63%	1.61%	0.69%	1.65%	0.31%	0.57%	0.61%	0.76%		7.84%
2024	0.24%	0.34%	1.38%	-0.58%	-0.24%	0.15%	3.63%	1.73%	1.20%	-0.18%	0.21%	-0.72%	7.31%
2023	0.19%	0.49%	-3.30%	1.06%	-2.92%	2.80%	1.59%	1.28%	0.04%	-2.11%	2.93%	1.08%	2.93%
2022	0.33%	0.80%	0.86%	-0.52%	-1.95%	-1.60%	2.13%	1.99%	-1.18%	-1.06%	-0.04%	0.57%	0.22%
2021	1.16%	0.30%	1.08%	1.58%	1.62%	-0.19%	-2.38%	-0.49%	0.60%	0.35%	-0.38%	1.04%	4.30%


PORTFOLIO STATISTICS SINCE 31/12/2004 AND FOR 5 YEARS

		ogne rbitrage	ES	TR	HFRX Global Hedge Fund EUR Index		
	5 years	From Start	5 years	From Start	5 years	From Start	
Cumulative Return	25.37%	447.10%	8.31%	21.64%	7.69%	-0.10%	
Annualised Return	4.62%	8.46%	1.61%	0.94%	1.49%	0.00%	
Annualised Volatility	4.55%	9.14%	0.52%	0.46%	2.99%	5.21%	
Sharpe Ratio	0.66	0.82	-	-	-0.04	-0.18	
Sortino Ratio	1.15	2.07	-	-	-0.07	-0.24	
Max Drawdown	-6.15%	-14.71%	-0.96%	-3.38%	-8.35%	-25.96%	
Time to Recovery (m)	6	46	7	16	23	> 68	
Positive Months (%)	71.67%	73.71%	63.33%	56.57%	58.33%	58.57%	

PERFORMANCE (Net Asset Value)



DISTRIBUTION OF RETURNS (Monthly Basis)



INVESTMENT MANAGERS' COMMENTARY

At the end of the year, the mergers and acquisitions market maintained a high volume of transactions, benefiting in particular from the official announcement of several jumbo deals in the United States. The most significant announcement in November was Kimberly-Clark's offer to acquire Kenvue, with the goal of creating a major global player in health and wellness. The value of the transaction amounts to approximately \$48bn. At the same time, Abbott Laboratories submitted a \$21.4bn bid to acquire oncology research company Exact Sciences, in order to strengthen its diagnostics division.

After a start to the month marked by heightened volatility and uneven performance across strategies, November ultimately helped improve year-to-date performance thanks to the narrowing of most spreads. The Surmodics and Avadel Pharmaceuticals deals were the main contributors. The first reached a positive outcome. The FTC had sought to block the transaction initiated by private equity firm GTCR in May 2024 on the grounds of "eliminating competition in the outsourced hydrophilic coatings market." The court ultimately rejected this request, thereby approving the sale proposed by the acquirer under the initial terms. The stock, which had been trading near pre-announcement levels, rose by 57% following the decision, and the deal has now closed. Avadel Pharmaceuticals, for its part, found itself at the center of a bidding war. The laboratory specializing in sleep disorders had initially accepted Alkermes' offer of \$18.50 per share plus a CVR worth up to \$1.50. Three weeks later, Danish company Lundbeck submitted an unsolicited competing proposal of \$21 per share plus a CVR worth up to \$2. While the target's board viewed this offer as superior, discussions between Avadel and Alkermes ultimately led to an improved offer of \$21 plus a CVR worth up to \$1.50. As we had invested as soon as the first announcement was made, we were able to benefit from this situation and began reducing our position without waiting for a potential counteroffer from Lundbeck. Finally, we mainly allocated capital to transactions nearing completion or presenting, in our view, limited residual risk. The Interpublic Group / Omnicom Group, Covestro and Spectris strategies thus contributed to increasing our leverage at the end of the month. The corresponding payments, however, are expected in December for each of these transactions.

Construction 9% Insurance 6% Real Estate 4% Industrial Services 19% Media Others 12%

CORRELATION MATRIX						
	Cigogne M&A Arbitrage	ESTR	HFRX Global Hedge Fund EUR Index			
Cigogne M&A	100.00% 11.80%		56.24%			
ESTR	11.80%	100.00%	16.01%			
HFRX HF Index	56.24%	16.01%	100.00%			

CIGOGNE FUND

M&A Arbitrage 30/11/2025



€

INVESTMENT OBJECTIVES

The choice of the assets is guided by an arbitration of mergers and/or acquisitions, consisting in benefiting from the price differences, which can appear at the time of takeover bids or exchange. Based on a solid and detailed analysis of the economic, legal and competitive frameworks, initiated operations are mainly held until the finalization of the offer. The portfolio only focuses on declared M&A situations. Initiated strategies consist in acquiring shares of the target company (cash offer) and selling shares of the acquirer (stock, cash and stock offer) or conversely if we expect the bid to fail. The sub-fund may also develop strategies on corporate action arbitrage such as preferential subscription rights.

FUND SPECIFICS

Net Asset Value : Net Asset Value (O Unit) : Liquidative Value (O Unit) : ISIN Code :

Legal Structure : Inception Date of the fund : Inception Date (O Unit) :

Currency :

NAV calculation date:

Subscription / redemption : Minimum Commitment: Minimum Notice Period: FCP - SIF, AIF November 16th 2004 November 16th 2004 EUR

196 908 968 67

38 188 302.22

LU0648563830

54 778.05

Monthly, last calendar day of the month

Monthly 100 000.00 1 month

MAIN EXPOSURES (In percentage of gross asset base)

COVESTRO	8.62%
INTERPUBLIC GROUP OMNICOM GROUP	6.22%
SCSK	3.83%
SPECTRIS	2.77%
GRUPO CATALANA OCCIDENTE	2.72%

Management Fee: Performance Fee:

Country of Registration : Management Company: Investment Advisor: Depositary Bank: Administrative Agent: Auditor:

1,50% per annum 20% above €STR with a High Water Mark

FR, LU
Cigogne Management SA
CIC Marchés
Banque de Luxembourg
UI efa
KPMG Luxembourg

RISK PROFILE

Lower Risl	K	F	ligher Risk			
Potentially low	Potentially	Potentially higher Return				
1	2	3	4	5	6	7

The risk category has been determined on the basis of historical data and may not be a reliable indication of the future risk profile. The risk and reward category shown does not necessarily remain unchanged and the categorization of the fund may shift over time.

REASONS TO INVEST IN CIGOGNE M&A ARBITRAGE

In addition to traditional financial investment, alternative investments aim to provide investors with absolute performances independent from the return of traditional asset classes such as shares, bonds etc. With these objectives, alternative investments can be construed as the natural complement to assets allocation between classical portfolio investment and risks managed performance strategies that take advantages of market inefficiencies.

Cigogne Management S.A. is the alternative asset management branch of Crédit Mutuel Alliance Fédérale, a major actor in the industry. Cigogne Management S.A. benefits from CIC Marchés' deep expertise. Cigogne Management S.A. currently manages the Cigogne Fund, Cigogne UCITS and Cigogne CLO Arbitrage funds (single-strategy funds) as well as the Stork Fund (multi-strategy funds).

Cigogne Fund - M&A Arbitrage aims to achieve stable and positive performances over time, uncorrelated from traditional asset classes by setting up arbitrage strategies taking advantage of disrupted and modified interest rate curves.

DISCLAIMER

The information contained herein is provided for information purposes only and shall only be valid at the time it is given. No guarantee can be given as to the exhaustiveness timeliness or accuracy of this information. Past performance is no indication of future returns. Any investment may generate losses or gains. The information on this document is not intended to be an offer or solicitation to invest or to provide any investment service or advice. Potentially interested persons must consult their own legal and tax advisor on the possible consequences under the laws of their country of citizenship or domicile. Any person must carefully consider the suitability of their investments to their specific situation and ensure that they understand the risks involved. Subscriptions to fund shares will only be accepted on the basis of the latest prospectus and the most recent annual reports.

CONTACT

CIGOGNE MANAGEMENT S.A.

18 Boulevard Royal
L - 2449 Luxembourg
LUXEMBOURG

www.cigogne-management.com

contact@cigogne-management.com

